dm+d
Unassigned
New Medicines
Erythropoietic protoporphyria (EPP) in adults - first-line
Information
New molecular entity
Mitsubishi Tanabe
Mitsubishi Tanabe
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Category
Stimulates melanocyte receptor MC1R
EPP affects between 1 in 50,000 to 75,000 people [1].
Erythropoietic protoporphyria (EPP) in adults - first-line
Oral